Cargando…

Nirmatrelvir and ritonavir for COVID-19

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	NPS MedicineWise 2022
Materias:	New Drugs
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081944/ https://www.ncbi.nlm.nih.gov/pubmed/35592371 http://dx.doi.org/10.18773/austprescr.2022.015

Ejemplares similares

Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
por: Blair, Hannah A.
Publicado: (2022)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Pharmacokinetic interaction between verapamil and ritonavir-boosted nirmatrelvir: implications for the management of COVID-19 in patients with hypertension
por: Haque, Obaid Imtiyazul, et al.
Publicado: (2023)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2023)

Molnupiravir for COVID-19
Publicado: (2022)

Remdesivir for COVID-19
Publicado: (2020)

Sotrovimab for COVID-19
Publicado: (2021)

Casirivimab and imdevimab for COVID-19
Publicado: (2022)

Elasomeran for prevention of COVID-19
Publicado: (2021)

Elasomeran/imelasomeran for prevention of COVID-19
Publicado: (2022)

Tixagevimab and cilgavimab for COVID-19 prophylaxis
Publicado: (2022)

Elasomeran+davesomeran for prevention of COVID-19
Publicado: (2023)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
por: Hung, Yuan-Pin, et al.
Publicado: (2022)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
por: Patel, Dimple, et al.
Publicado: (2023)

523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023)

483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Tozinameran+riltozinameran and tozinameran+famtozinameran for prevention of COVID-19
Publicado: (2023)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

ChAdOx1-S vaccine for prevention of COVID-19
Publicado: (2021)

Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
por: Catalán, Ignacio Pérez, et al.
Publicado: (2023)

Best regimen for elexacaftor/ivacaftor/tezacaftor with nirmatrelvir-ritonavir for COVID-19?
Publicado: (2022)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
por: Cao, Zhujun, et al.
Publicado: (2022)

Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
por: Kim, Haein, et al.
Publicado: (2022)

Ritonavir-boosted Nirmatrelvir and COVID-19 outcomes in the age of Omicron variant
por: Imran, Laiba, et al.
Publicado: (2023)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2023)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
por: Qiu, Chaochao, et al.
Publicado: (2023)

SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19
Publicado: (2022)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Three COVID-19 medications-remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir-and serial liver biochemistries in 22, 456 subjects
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment
por: Carlin, Aaron F., et al.
Publicado: (2022)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022)

Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
por: Buxeraud, Jacques, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_cgall7v497ql0l94kjvm9i83q3